Effectiveness trials: critical data to help understand how respiratory medicines really work?

• Main Authors: Andreas Heddini, Josefin Sundh, Magnus Ekström, Christer Janson
• Format: Article
• Language: English
• Published: Taylor & Francis Group 2019-01-01
• Series: European Clinical Respiratory Journal
• Subjects: effectiveness; real-world evidence; pragmatic trials; evidence-base; efficacy rct; levels of evidence; respiratory disease; asthma; copd; co-morbidity
• Online Access: http://dx.doi.org/10.1080/20018525.2019.1565804

Most of the information about the benefits, safety aspects, and cost effectiveness of pharmacological treatment in the respiratory field has been obtained from traditional efficacy studies, such as randomised controlled trials (RCT). The highly controlled environment of an RCT does not always reflect everyday practice. The collection, analysis, and application of effectiveness data to generate Real World Evidence (RWE) through pragmatic trials or observational studies therefore has the potential to improve decision making by regulators, payers, and clinicians. Despite calls for more RWE, effectiveness data are not widely used in decision making in the respiratory field. Recent advances in data capture, curation, and storage combined with new analytical tools have now made it feasible for effectiveness data to become routine sources of evidence to supplement traditional efficacy data. In this paper, we will examine some of the current data gaps, diverse types of effectiveness data, look at proposed frameworks for the positioning of effectiveness data, as well as provide examples from therapeutic areas. We will give examples of both previous effectiveness studies and studies that are ongoing within the respiratory field. Effectiveness data hold the potential to address several evidentiary gaps related to the effectiveness, safety, and value of treatments in patients with respiratory diseases.